Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs McKesson Corporation — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $92.83 (market cap $5.86B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 18.5× State Street SPDR Bloomberg High Yield Bond ETF's market cap, and McKesson Corporation pays a 0.4% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg High Yield Bond ETF for 61 Days and McKesson Corporation for 74 Days on average.
| JNK | MCK | |
|---|---|---|
Market Cap | $5.86B | $108.46B |
Volume | 7,780,002 | 712,607 |
Sector | Fixed Income | Health |
52-Week High | $98.02 | $995.69 |
52-Week Low | $92.30 | $725.17 |
Typical Hold Time | 61 Days | 74 Days |
Enterprise Value | — | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK trades at $92.73, down slightly by 0.03% with a bearish technical signal from moving averages. The ETF maintains consistent dividend payments of $0.53 per share through 2026. Recent institutional activity shows Envestnet Asset Management increased its stake by 23.3% during the latest quarter, indicating institutional confidence despite broader market volatility in high-yield bonds.
The outlook remains cautious amid rising Treasury yields and geopolitical tensions affecting bond markets. Key risks include interest rate sensitivity and economic slowdown concerns. Current technical support sits at $92 with resistance at $93, suggesting limited near-term price movement absent significant market catalysts.
McKesson (MCK) trades at $930.25, up 2.19% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins are thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing long-term visibility.
The outlook is positive, driven by operational strength and strategic partnerships, but investors face risks from margin pressure and drug pricing uncertainty. With 81% of analysts rating it Buy and a consensus target of $956.43, the stock offers upside, though high RSI levels suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
